WO2012060790A2 - Water dispersible cefpodoxime proxetil formulations - Google Patents
Water dispersible cefpodoxime proxetil formulations Download PDFInfo
- Publication number
- WO2012060790A2 WO2012060790A2 PCT/TR2011/000255 TR2011000255W WO2012060790A2 WO 2012060790 A2 WO2012060790 A2 WO 2012060790A2 TR 2011000255 W TR2011000255 W TR 2011000255W WO 2012060790 A2 WO2012060790 A2 WO 2012060790A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- agent
- composition according
- range
- carboxymethyl cellulose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Definitions
- the present invention relates to pharmaceutical formulations comprising cefpodoxime and optionally clavulanic acid or derivatives thereof.
- Cefpodoxime proxetil is a third generation cephalosporin. Due to this feature, it is indicated for the treatment of infections caused by gram positive and gram negative bacteria.
- Clavulanic acid and derivatives thereof are known as the beta-lactamase inhibitors which withstand the beta-lactamase-originated resistance mechanism by suppressing the activity of beta-lactamase enzymes produced by bacteria.
- Clavulanic acid and derivatives thereof can optionally be formulated as combined with antibiotics in order to increase efficiency of beta-lactam derivative antibiotics.
- Tablets which contain 100 mg and 200 mg of cefpodoxime are available on the market. When these tablets containing 100 or 200 mg of active agent are formulated with excipients, they become quite large in size and this makes use of this dosage form inconvenient for patients who have swallowing difficulties, especially for pediatric and geriatric patients.
- cefpodoxime proxetil has quite low water solubility; therefore bioavailability of tablet forms thereof is rather low. It is known that efficiency of a drug depends on the design of the pharmaceutical formulation to a great extent. When highly hydrophobic nature of cephalosporins, especially DCpodoxime, are taken into consideration, it is seen that selecting each agent to be used in the formulation carefully is significant to attain to the desired level of bioavailability in the dosage forms constituted.
- the subject matter of the present invention is formulations comprising water dispersible cefpodoxime which comprise a viscosity agent consisting of hydroxypropyl cellulose and at least one carboxymethyl cellulose derivative agent combination and optionally clavulanic acid or derivatives thereof. It has surprisingly been seen that powder, tablet and/or granules comprising the active agent cefpodoxime, which has rather low solubility, and formulated with the viscosity agent comprising the combination of hydroxypropyl cellulose and at least one carboxymethyl cellulose derivative agent constitute a suspension which is dispersed in water without gelling.
- pharmaceutical dosage forms in the form of water dispersible powder, tablet and/or granule a) can be taken by patients more comfortably than the solid dosage forms as they disperse in water homogeneously and their bioavailability is superior to said solid dosage forms; b) thus, the problem of gelling which is frequently encountered in cefpodoxime formulations is overcome in this way.
- Cefpodoxime that can be used in water dispersible powder, tablet and/or granule formulations of the present invention can be in the form of its esters, solvates, hydrates, enantiomers, racemates, organic salts, inorganic salts, polymorphs, crystalline and amorphous forms or free form and/or a combination thereof.
- cefpodoxime proxetil is used in the present invention.
- water dispersible powder , tablet and/or granule comprises single dose effervescent powder, tablets and/or granules; single dose water dispersible powder, tablets and granules; multiple dose powder, tablets and granules which are dispersed in water to form suspension; single dose water soluble powder, tablets and granules; multiple dose water soluble powder, tablets and granules, preferably in the form of multiple dose powder dispersed in water to form suspension or single dose water dispersible powder, tablets or granules.
- one aspect of the present invention is water dispersible powder, tablet and/or granule formulations comprising cefpodoxime as the active agent and viscosity agent composition comprising hydroxypropyl cellulose and at least one carboxymethyl cellulose derivative agent combination.
- Another aspect of the present invention is water dispersible powder, tablet and/or granule formulations comprising cefpodoxime as the active agent; viscosity agent composition comprising hydroxypropyl cellulose and at least one carboxymethyl cellulose derivative agent combination; and additionally other pharmaceutically acceptable excipients.
- the water dispersible powder, tablet and/or granule formulation can comprise various excipients such as, but not limited to, binders, glidants, lubricants, humectants, disintegrants, diluents, basic agents, acidic agents, taste regulating agents, flavoring agents, preservative agents and optionally effervescent couple.
- excipients such as, but not limited to, binders, glidants, lubricants, humectants, disintegrants, diluents, basic agents, acidic agents, taste regulating agents, flavoring agents, preservative agents and optionally effervescent couple.
- the binder that can be used in water dispersible powder, tablet and granule formulation of the present invention can be selected from a group comprising ethyl cellulose, gelatine, hydroxyethyl cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, hypromellose, magnesium aluminum silicate, methyl cellulose, povidone or the combination thereof.
- the lubricant that can be used in water dispersible powder, tablet and granule formulation of the present invention can be selected from a group comprising calcium stearate, magnesium stearate, polyethylene glycol, PEG 6000, polyvinyl alcohol, potassium benzoate, talc, sodium benzoate or the combination thereof.
- talc is used as lubricant in the formulation of the present invention.
- the glidant that can be used in the water dispersible powder, tablet and granule formulation of the present invention can be selected from a group comprising magnesium silicate, silicon dioxide, starch, talc, tribasic calcium phosphate or the combination thereof.
- silicon dioxide is used as glidant in the formulation of the present invention.
- the humectant that can be used in the water dispersible powder, tablet and granule formulation of the present invention can be selected from a group comprising anhydrous sodium sulphate, silica gel and potassium carbonate or the combination thereof.
- the disintegrant that can be used in water dispersible powder, tablet and granule formulation of the present invention can be selected from a group comprising carboxymethyl cellulose calcium, carboxymethyl cellulose sodium, microcrystalline cellulose, silicon dioxide, croscarmellose sodium, crospovidone, hydroxypropyl cellulose, methyl cellulose, povidone, magnesium aluminum silicate and starch or combinations thereof.
- the diluent that can be used in water dispersible powder, tablet and granule formulation of the present invention can be selected from a group comprising calcium carbonate, calcium sulphate, dibasic calcium phosphate, tribasic calcium phosphate, calcium sulphate, microcrystalline cellulose, lactose, magnesium carbonate, magnesium oxide, maltodextrin, maltose, mannitol, sodium chloride, sorbitol, starch, xylitol or combinations thereof.
- the basic agent that can be used in the water dispersible powder, tablet and/or granule formulation of the present invention can be selected from a group comprising potassium carbonate, potassium bicarbonate, potassium citrate, potassium hydroxide, sodium carbonate, sodium bicarbonate or combinations thereof.
- the acidic agent that can be used in the water dispersible powder, tablet and/or granule formulation of the present invention can be selected from a group comprising acetic acid, citric acid, lactic acid, malic acid, phosphoric acid, propionic acid, tartaric acid or combinations thereof.
- citric acid is used in the formulation of the present invention as acidic agent.
- the taste regulating agent that can be used in water dispersible powder, tablet and/or granule formulation of the present invention can be selected from a group comprising acesulfame, aspartame, dextrose, fructose, glucose, lactitol, maltitol, maltose, sorbitol, saccharine, saccharine sodium, sodium cyclamate, sucralose, sodium chloride, potassium chloride, sucrose, xylitol or combinations thereof.
- the preservative agent that can be used in water dispersible powder, tablet and granule formulation of the present invention can be selected from a group comprising methylparaben, ethylparaben, butylparaben, sorbic acid, tertiary ammonium salts, potassium sorbate, benzoic acid and/or salts thereof (sodium benzoate) and benzyl alcohol or combinations thereof.
- the effervescent couple that can optionally be used in water dispersible powder, tablet and granule formulation of the present invention can be selected from organic acids such as citric acid, tartaric acid, malic acid, fumaric acid etc. and basic agents such as sodium hydrogen carbonate, sodium carbonate, potassium carbonate and potassium hydrogen carbonate etc.
- the viscosity agent that can be used in water dispersible powder, tablet and/or granule formulation of the present invention is composed of hydroxypropyl cellulose and at least one carboxymethylcellulose derivative agent.
- the ratio of the carboxymethyl cellulose derivative agents to hydroxypropyl cellulose used in viscosity agent combination of the present invention is in the range of 15:1 and 5:1 by weight, preferably in the range of 12:1 and 6:1 by weight, more preferably in the range of 10:1 and 7:1 by weight.
- carboxymethyl derivative agent refers to alkali and alkaline- earth salts of carboxymethyl cellulose.
- Carboxymethyl cellulose derivative agent can be selected from a group comprising carboxymethyl cellulose calcium, carboxymethyl cellulose sodium or combinations thereof.
- the inventors have found that water dispersity of a pharmaceutical composition obtained by use of combination of carboxymethyl cellulose sodium and carboxymethyl cellulose calcium is better than the other pharmaceutical compositions in which only one of said agents is used.
- present invention relates to water dispersible cefpodoxime formulations comprising a viscosity agent combination comprising hydroxypropyl cellulose, carboxymethyl cellulose sodium and carboxymethyl cellulose calcium.
- the ratio of carboxymethyl cellulose calcium to carboxymethyl cellulose sodium in said viscosity agent combination is in the range of 5: 1 and 1 :1 by weight, preferably in the range of 4:1 and 2:1 by weight.
- the water dispersible powder, tablet and granule formulation of the present invention can comprise cefpodoxime in the range of 20-800 mg or its pharmaceutically acceptable esters, salts, hydrates, solvates or a combination thereof in an equal amount.
- the water dispersible powder, tablet and granule formulation of the present invention can comprise 5-60% of cefpodoxime or its pharmaceutically acceptable esters, solvates, hydrates, enantiomers, racemates, organic salts, inorganic salts, polymorphs, crystalline and amorphous forms in proportion to total weight of unit dose.
- the water dispersible powder, tablet and granule formulation of the present invention can comprise 5-60 % of cefpodoxime and at least one; binder in the range of 0-40%; glidant in the range of 0.5-5%; lubricant in the range of 1-10%; humectant in the range of 0-40%; disintegrant and/or disintegrants in the range of 0-20%; diluent in the range of 35-65%; basic agent in the range of 0-40%; acidic agent in the range of 0.1-40%; taste regulating agent in the range of 5-30%; viscosity agent in the range of 2-15%; flavoring agent in the range of 0.1-5%; preservative agent in the range of 0-5% and optionally effervescent couple in the range of 0- 85% in proportion to the total weight of unit dose amount.
- the formulation of the present invention can be used for pharmaceutical ⁇ compositions comprising clavulanic acid or derivatives thereof along with cefpodoxime.
- the present invention relates to pharmaceutical compositions comprising cefpodoxime and clavulanic acid or derivatives thereof, viscosity agent composition comprising hydroxypropyl cellulose and at least one carboxymethyl cellulose derivative agent combination; and optionally pharmaceutically acceptable excipients in addition.
- Clavulanic acid that can optionally be used in the pharmaceutical composition of the present invention can be in the form of its solvates, hydrates, enantiomers, racemates, organic salts, inorganic salts, polymorphs, crystalline and amorphous forms or in free form and/or a combination thereof.
- potassium clavulanate is used in the present invention.
- the pharmaceutical composition of the present invention can comprise clavulanic acid in the range of 50-500 mg or its pharmaceutically acceptable salts, hydrates, solvates or the combination thereof in an equal amount.
- Clavulanic acid and its derivatives are extremely susceptible to moisture.
- potassium clavulanate is preferably used with a humectant in the ratio of 1 :1 in the pharmaceutical composition of the present invention.
- colloidal silica for instance colloidal silica anhydrous, magnesium trisilicate, cellulose powder, magnesium oxide, calcium silicate, starch, microcrystalline cellulose, talc can be used as the humectant.
- potassium clavulanate is preferably used with syloid in the ratio of 1 : 1.
- the pharmaceutical composition of the present invention can comprise 5-50% of clavulanic acid in proportion to total weight of unit dose amount or pharmaceutically acceptable salts, hydrates, solvates or combinations thereof in an equal amount.
- the present invention relates to processes that can be used for preparation of water dispersible powder, tablet and/or granule formulations comprising pharmaceutically acceptable excipients in addition to cefpodoxime as the active agent.
- the process of the present invention comprises granulation of the active agent cefpodoxime proxetil by conventional wet and/or dry granulation methods; or powdering cefpodoxime proxetil and other excipients after mixing them by dry blending method and optionally compressing tablets.
- the powder, tablet and/or granules obtained are dispersed in water before use by patients and taken in liquid form.
- Another aspect of the present invention is that the formulation prepared according to said invention is used in the treatment of diseases related with infections caused by gram negative and gram positive bacteria.
- Water dispersible tablets of the present invention can be prepared as specified below, yet the invention is not restricted to these examples.
- EXAMPLE 1 Formulation and process for preparation of water dispersible granule
- a method for preparation of water dispersible granule given in the example comprises, but not limited to, dissolving cefpodoxime proxetil in a suitable solvent; and granulating the diluent with this solution; and drying and then mixing the obtained granules with the other excipients.
- a method for preparation of water dispersible granule given in this example comprises, but not limited to, dissolving cefpodoxime proxetil in a suitable solvent; and granulating the diluent with this solution; and drying and then mixing the granules obtained with potassium clavylanate-syloid (1 :1) and the other excipients.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cephalosporin Compounds (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to pharmaceutical formulations comprising cefpodoxi proxetil.
Description
WATER DISPERSIBLE CEFPODOXIME PROXETIL FORMULATIONS
The present invention relates to pharmaceutical formulations comprising cefpodoxime and optionally clavulanic acid or derivatives thereof.
Background of the Invention:
Cefpodoxime proxetil (Figure I), chemical name of which pivaloyloxymethyl 7-[2-(2-amino- thiazole-4-yl]-2-(syn)-methoxyimino-acetamido]-3-methoxymethyl-3-cefem-4-carboxylate, was first disclosed in the patent number EP0049118.
Figure 1
Cefpodoxime proxetil is a third generation cephalosporin. Due to this feature, it is indicated for the treatment of infections caused by gram positive and gram negative bacteria.
Clavulanic acid and derivatives thereof (for instance its salts such as potassium clavulanate) are known as the beta-lactamase inhibitors which withstand the beta-lactamase-originated resistance mechanism by suppressing the activity of beta-lactamase enzymes produced by bacteria. Clavulanic acid and derivatives thereof can optionally be formulated as combined with antibiotics in order to increase efficiency of beta-lactam derivative antibiotics.
Tablets which contain 100 mg and 200 mg of cefpodoxime are available on the market. When these tablets containing 100 or 200 mg of active agent are formulated with excipients, they become quite large in size and this makes use of this dosage form inconvenient for patients who have swallowing difficulties, especially for pediatric and geriatric patients.
The molecule cefpodoxime proxetil has quite low water solubility; therefore bioavailability of tablet forms thereof is rather low.
It is known that efficiency of a drug depends on the design of the pharmaceutical formulation to a great extent. When highly hydrophobic nature of cephalosporins, especially ceipodoxime, are taken into consideration, it is seen that selecting each agent to be used in the formulation carefully is significant to attain to the desired level of bioavailability in the dosage forms constituted.
In order to overcome the problems that solid dosage forms pose, water dispersible dosage forms have been developed. However, the fact that ceipodoxime has rather low water solubility makes development of water dispersible cefpodoxime formulations difficult.
At this point, there is need for formulations comprising cefpodoxime and optionally clavulanic acid or derivatives thereof which have higher bioavailability than solid oral dosage forms; can dissolve in water; have no gelling problem in order to meet the needs of the patients in special conditions, for example pediatric and geriatric patients.
Description of the Invention:
The subject matter of the present invention is formulations comprising water dispersible cefpodoxime which comprise a viscosity agent consisting of hydroxypropyl cellulose and at least one carboxymethyl cellulose derivative agent combination and optionally clavulanic acid or derivatives thereof. It has surprisingly been seen that powder, tablet and/or granules comprising the active agent cefpodoxime, which has rather low solubility, and formulated with the viscosity agent comprising the combination of hydroxypropyl cellulose and at least one carboxymethyl cellulose derivative agent constitute a suspension which is dispersed in water without gelling.
According to this, pharmaceutical dosage forms in the form of water dispersible powder, tablet and/or granule; a) can be taken by patients more comfortably than the solid dosage forms as they disperse in water homogeneously and their bioavailability is superior to said solid dosage forms; b) thus, the problem of gelling which is frequently encountered in cefpodoxime formulations is overcome in this way.
Cefpodoxime that can be used in water dispersible powder, tablet and/or granule formulations of the present invention can be in the form of its esters, solvates, hydrates, enantiomers, racemates, organic salts, inorganic salts, polymorphs, crystalline and amorphous forms or free
form and/or a combination thereof. Preferably, cefpodoxime proxetil is used in the present invention.
The term "water dispersible powder , tablet and/or granule" stated in the text comprises single dose effervescent powder, tablets and/or granules; single dose water dispersible powder, tablets and granules; multiple dose powder, tablets and granules which are dispersed in water to form suspension; single dose water soluble powder, tablets and granules; multiple dose water soluble powder, tablets and granules, preferably in the form of multiple dose powder dispersed in water to form suspension or single dose water dispersible powder, tablets or granules.
According to this, one aspect of the present invention is water dispersible powder, tablet and/or granule formulations comprising cefpodoxime as the active agent and viscosity agent composition comprising hydroxypropyl cellulose and at least one carboxymethyl cellulose derivative agent combination.
Another aspect of the present invention is water dispersible powder, tablet and/or granule formulations comprising cefpodoxime as the active agent; viscosity agent composition comprising hydroxypropyl cellulose and at least one carboxymethyl cellulose derivative agent combination; and additionally other pharmaceutically acceptable excipients.
Apart from cefpodoxime and viscosity agent composition comprising hydroxypropyl cellulose and at least one carboxymethyl cellulose derivative agent combination; the water dispersible powder, tablet and/or granule formulation can comprise various excipients such as, but not limited to, binders, glidants, lubricants, humectants, disintegrants, diluents, basic agents, acidic agents, taste regulating agents, flavoring agents, preservative agents and optionally effervescent couple.
The binder that can be used in water dispersible powder, tablet and granule formulation of the present invention can be selected from a group comprising ethyl cellulose, gelatine, hydroxyethyl cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, hypromellose, magnesium aluminum silicate, methyl cellulose, povidone or the combination thereof.
The lubricant that can be used in water dispersible powder, tablet and granule formulation of the present invention can be selected from a group comprising calcium stearate, magnesium stearate, polyethylene glycol, PEG 6000, polyvinyl alcohol, potassium benzoate, talc, sodium
benzoate or the combination thereof. Preferably, talc is used as lubricant in the formulation of the present invention.
The glidant that can be used in the water dispersible powder, tablet and granule formulation of the present invention can be selected from a group comprising magnesium silicate, silicon dioxide, starch, talc, tribasic calcium phosphate or the combination thereof. Preferably, silicon dioxide is used as glidant in the formulation of the present invention.
The humectant that can be used in the water dispersible powder, tablet and granule formulation of the present invention can be selected from a group comprising anhydrous sodium sulphate, silica gel and potassium carbonate or the combination thereof.
The disintegrant that can be used in water dispersible powder, tablet and granule formulation of the present invention can be selected from a group comprising carboxymethyl cellulose calcium, carboxymethyl cellulose sodium, microcrystalline cellulose, silicon dioxide, croscarmellose sodium, crospovidone, hydroxypropyl cellulose, methyl cellulose, povidone, magnesium aluminum silicate and starch or combinations thereof.
The diluent that can be used in water dispersible powder, tablet and granule formulation of the present invention can be selected from a group comprising calcium carbonate, calcium sulphate, dibasic calcium phosphate, tribasic calcium phosphate, calcium sulphate, microcrystalline cellulose, lactose, magnesium carbonate, magnesium oxide, maltodextrin, maltose, mannitol, sodium chloride, sorbitol, starch, xylitol or combinations thereof.
The basic agent that can be used in the water dispersible powder, tablet and/or granule formulation of the present invention can be selected from a group comprising potassium carbonate, potassium bicarbonate, potassium citrate, potassium hydroxide, sodium carbonate, sodium bicarbonate or combinations thereof.
The acidic agent that can be used in the water dispersible powder, tablet and/or granule formulation of the present invention can be selected from a group comprising acetic acid, citric acid, lactic acid, malic acid, phosphoric acid, propionic acid, tartaric acid or combinations thereof. Preferably, citric acid is used in the formulation of the present invention as acidic agent.
The taste regulating agent that can be used in water dispersible powder, tablet and/or granule formulation of the present invention can be selected from a group comprising acesulfame,
aspartame, dextrose, fructose, glucose, lactitol, maltitol, maltose, sorbitol, saccharine, saccharine sodium, sodium cyclamate, sucralose, sodium chloride, potassium chloride, sucrose, xylitol or combinations thereof.
The preservative agent that can be used in water dispersible powder, tablet and granule formulation of the present invention can be selected from a group comprising methylparaben, ethylparaben, butylparaben, sorbic acid, tertiary ammonium salts, potassium sorbate, benzoic acid and/or salts thereof (sodium benzoate) and benzyl alcohol or combinations thereof.
The effervescent couple that can optionally be used in water dispersible powder, tablet and granule formulation of the present invention can be selected from organic acids such as citric acid, tartaric acid, malic acid, fumaric acid etc. and basic agents such as sodium hydrogen carbonate, sodium carbonate, potassium carbonate and potassium hydrogen carbonate etc.
The viscosity agent that can be used in water dispersible powder, tablet and/or granule formulation of the present invention is composed of hydroxypropyl cellulose and at least one carboxymethylcellulose derivative agent.
The ratio of the carboxymethyl cellulose derivative agents to hydroxypropyl cellulose used in viscosity agent combination of the present invention is in the range of 15:1 and 5:1 by weight, preferably in the range of 12:1 and 6:1 by weight, more preferably in the range of 10:1 and 7:1 by weight.
The term "carboxymethyl derivative agent" stated in the text refers to alkali and alkaline- earth salts of carboxymethyl cellulose.
Carboxymethyl cellulose derivative agent can be selected from a group comprising carboxymethyl cellulose calcium, carboxymethyl cellulose sodium or combinations thereof.
The inventors have found that water dispersity of a pharmaceutical composition obtained by use of combination of carboxymethyl cellulose sodium and carboxymethyl cellulose calcium is better than the other pharmaceutical compositions in which only one of said agents is used.
According to this, present invention relates to water dispersible cefpodoxime formulations comprising a viscosity agent combination comprising hydroxypropyl cellulose, carboxymethyl cellulose sodium and carboxymethyl cellulose calcium.
The ratio of carboxymethyl cellulose calcium to carboxymethyl cellulose sodium in said viscosity agent combination is in the range of 5: 1 and 1 :1 by weight, preferably in the range of 4:1 and 2:1 by weight.
The water dispersible powder, tablet and granule formulation of the present invention can comprise cefpodoxime in the range of 20-800 mg or its pharmaceutically acceptable esters, salts, hydrates, solvates or a combination thereof in an equal amount.
The water dispersible powder, tablet and granule formulation of the present invention can comprise 5-60% of cefpodoxime or its pharmaceutically acceptable esters, solvates, hydrates, enantiomers, racemates, organic salts, inorganic salts, polymorphs, crystalline and amorphous forms in proportion to total weight of unit dose.
The water dispersible powder, tablet and granule formulation of the present invention can comprise 5-60 % of cefpodoxime and at least one; binder in the range of 0-40%; glidant in the range of 0.5-5%; lubricant in the range of 1-10%; humectant in the range of 0-40%; disintegrant and/or disintegrants in the range of 0-20%; diluent in the range of 35-65%; basic agent in the range of 0-40%; acidic agent in the range of 0.1-40%; taste regulating agent in the range of 5-30%; viscosity agent in the range of 2-15%; flavoring agent in the range of 0.1-5%; preservative agent in the range of 0-5% and optionally effervescent couple in the range of 0- 85% in proportion to the total weight of unit dose amount.
If required, the formulation of the present invention can be used for pharmaceutical ι compositions comprising clavulanic acid or derivatives thereof along with cefpodoxime.
According to this, the present invention relates to pharmaceutical compositions comprising cefpodoxime and clavulanic acid or derivatives thereof, viscosity agent composition comprising hydroxypropyl cellulose and at least one carboxymethyl cellulose derivative agent combination; and optionally pharmaceutically acceptable excipients in addition.
» Clavulanic acid that can optionally be used in the pharmaceutical composition of the present invention can be in the form of its solvates, hydrates, enantiomers, racemates, organic salts, inorganic salts, polymorphs, crystalline and amorphous forms or in free form and/or a combination thereof. Preferably, potassium clavulanate is used in the present invention.
The pharmaceutical composition of the present invention can comprise clavulanic acid in the range of 50-500 mg or its pharmaceutically acceptable salts, hydrates, solvates or the combination thereof in an equal amount.
Clavulanic acid and its derivatives (e.g. potassium clavulanate) are extremely susceptible to moisture. To this respect, potassium clavulanate is preferably used with a humectant in the ratio of 1 :1 in the pharmaceutical composition of the present invention.
One or more of the substances comprising silica; colloidal silica, for instance colloidal silica anhydrous, magnesium trisilicate, cellulose powder, magnesium oxide, calcium silicate, starch, microcrystalline cellulose, talc can be used as the humectant.
In the pharmaceutical composition of the present invention, potassium clavulanate is preferably used with syloid in the ratio of 1 : 1.
The pharmaceutical composition of the present invention can comprise 5-50% of clavulanic acid in proportion to total weight of unit dose amount or pharmaceutically acceptable salts, hydrates, solvates or combinations thereof in an equal amount.
In another aspect, the present invention relates to processes that can be used for preparation of water dispersible powder, tablet and/or granule formulations comprising pharmaceutically acceptable excipients in addition to cefpodoxime as the active agent.
According to this, the process of the present invention comprises granulation of the active agent cefpodoxime proxetil by conventional wet and/or dry granulation methods; or powdering cefpodoxime proxetil and other excipients after mixing them by dry blending method and optionally compressing tablets.
The powder, tablet and/or granules obtained are dispersed in water before use by patients and taken in liquid form.
Another aspect of the present invention is that the formulation prepared according to said invention is used in the treatment of diseases related with infections caused by gram negative and gram positive bacteria.
Water dispersible tablets of the present invention can be prepared as specified below, yet the invention is not restricted to these examples.
EXAMPLE 1: : Formulation and process for preparation of water dispersible granule
A method for preparation of water dispersible granule given in the example comprises, but not limited to, dissolving cefpodoxime proxetil in a suitable solvent; and granulating the diluent with this solution; and drying and then mixing the obtained granules with the other excipients.
EXAMPLE 2: Formulation and process for preparation of water dispersible granule
A method for preparation of water dispersible granule given in this example comprises, but not limited to, dissolving cefpodoxime proxetil in a suitable solvent; and granulating the diluent with this solution; and drying and then mixing the granules obtained with potassium clavylanate-syloid (1 :1) and the other excipients.
Claims
1. A pharmaceutical composition comprising cefpodoxime characterised in that said composition is a water dispersible cefpodoxime formulation comprising viscosity agent composition which comprises hydroxypropyl cellulose and at least one carboxymethyl cellulose derivative agent combination.
2. The pharmaceutical composition according to claim 1, wherein cefpodoxime that is used as the active agent can be in the form of its esters, solvates, hydrates, enantiomers, racemates, organic salts, inorganic salts, polymorphs, crystalline and amorphous forms or in free form and/or a combination thereof.
3. The pharmaceutical composition according to claim 2, wherein cefpodoxime proxetil is used as the active agent.
4. The pharmaceutical composition according to claim 1, wherein said composition can be in the form of water dispersible powder, tablet and/or granules; single dose effervescent powder, tablets and/or granules; single dose water dispersible powders, tablets and/or granules; multiple dose powder, tablet and/or granules which are dispersed in water to form suspension; single dose water soluble powder, tablet and/or granules; multiple dose water soluble powder, tablet and/or granules.
5. The pharmaceutical composition according to claim 1, wherein said composition further comprises pharmaceutically acceptable excipients in addition to cefpodoxime used as the active agent and viscosity agent composition comprising hydroxypropyl cellulose and at least one carboxymethyl cellulose derivative agent combination.
6. The pharmaceutical composition according to claim 5, wherein said composition can comprise binder, glidant, lubricant, humectant, disintegrant, diluent, basic agent, acidic agent, taste regulating agent, viscosity agent, flavoring agent, preservative agent and/or effervescent couple in addition to cefpodoxime used as the active agent and viscosity agent composition comprising hydroxypropyl cellulose and at least one carboxymethyl cellulose derivative agent.
7. The pharmaceutical composition according to claim 6, wherein the binder can be selected from a group comprising ethyl cellulose, gelatine, hydroxyethyl cellulose, hydroxymethyl
I cellulose, hydroxypropyl cellulose, hypromellose, magnesium aluminum silicate, methyl cellulose, povidone or the combination thereof.
8. The pharmaceutical composition according to claim 6, wherein the lubricant can be selected from a group comprising calcium stearate, magnesium stearate, polyethylene glycol, PEG 6000, polyvinyl alcohol, potassium benzoate, talc, sodium benzoate or the combination thereof.
9. The pharmaceutical composition according to claim 8, wherein talc is preferably used as lubricant.
10. The pharmaceutical composition according to claim 6, wherein the glidant can be selected from a group comprising magnesium silicate, silicon dioxide, starch, talc, tribasic calcium phosphate or a combination thereof.
11. The pharmaceutical composition according to claim 10, wherein silicon dioxide is preferably used as glidant.
12. The pharmaceutical composition according to claim 6, wherein the humectant can be selected from a group comprising anhydrous sodium sulphate, silica gel and potassium carbonate or a combination thereof.
13. The pharmaceutical composition according to claim 6, wherein the disintegrant can be selected from a group comprising carboxymethyl cellulose calcium, carboxymethylcellulose sodium, microcrystalline cellulose, silicon dioxide, croscarmellose sodium, crospovidone, hydroxypropyl cellulose, methyl cellulose, povidone, magnesium aluminum silicate, starch or combinations thereof.
14. The pharmaceutical composition according to claim 6, wherein the diluent can be selected from a group comprising calcium carbonate, calcium sulphate, dibasic calcium phosphate, tribasic calcium phosphate, calcium sulphate, microcrystalline cellulose, lactose, magnesium carbonate, magnesium oxide, maltodextrin, maltose, mannitol, sodium chloride, sorbitol, starch, xylitol or combinations thereof.
15. The pharmaceutical composition according to claim 6, wherein the basic agent can be selected from a group comprising potassium carbonate, potassium bicarbonate, potassium citrate, potassium hydroxide, sodium carbonate, sodium bicarbonate or combinations thereof.
16. The pharmaceutical composition according to claim 6, wherein the acidic agent can be selected from a group comprising acetic acid, citric acid, lactic acid, malic acid, phosphoric acid, propionic acid, tartaric acid or combinations thereof.
17. The pharmaceutical composition according to claim 16, wherein citric acid is preferably used as acidic agent.
18. The pharmaceutical composition according to claim 6, wherein the taste regulating agent can be selected from a group comprising acesulfame, aspartame, dextrose, fructose, glucose, lactitol, maltitol, maltose, sorbitol, saccharine, saccharine sodium, sodium cyclamate, sucralose, sodium chloride, potassium chloride, sucrose, xylitol or combinations thereof.
19. The pharmaceutical composition according to claim 6, wherein the preservative agent can be selected from a group comprising methylparaben, ethylparaben, butylparaben, sorbic acid, tertiary ammonium salts, potassium sorbate, benzoic acid and/or salts thereof (sodium benzoate) and benzyl alcohol or a combination thereof.
20. The pharmaceutical composition according to claim 6, wherein the effervescent couple can be selected from organic acids such as citric acid, tartaric acid, malic acid, fumaric acid etc. and basic agents such as sodium hydrogen carbonate, sodium carbonate, potassium carbonate and potassium hydrogen carbonate etc..
21. The pharmaceutical composition according to claim 1, wherein the ratio of carboxymethyl cellulose derivative agent to hydroxypropyl cellulose used in the viscosity agent combination of said pharmaceutical composition is in the range of 15:1 and 5:1 by weight.
22. The pharmaceutical composition according to claim 21, wherein the ratio of carboxymethyl cellulose derivative agent to hydroxypropyl cellulose used in the viscosity agent combination of said pharmaceutical composition is in the range of 12:1 and 6:1 by weight.
23. The pharmaceutical composition according to claim 22, wherein the ratio of carboxymethyl cellulose derivative agent to hydroxypropyl cellulose used in the viscosity agent combination of said pharmaceutical composition is in the range of 10:1 and 7:1 by weight.
24. The pharmaceutical composition according to claim 21, wherein carboxymethyl cellulose derivative agent is selected from carboxymethyl cellulose calcium, carboxymethyl cellulose sodium or a combination thereof.
25. The pharmaceutical composition according to claim 24, wherein carboxymethyl cellulose derivative agent is composed of carboxymethyl cellulose calcium and carboxymethyl cellulose sodium combination.
26. The pharmaceutical composition according to claim 25, wherein the ratio of carboxymethyl cellulose calcium to carboxymethyl cellulose sodium is in the range of 5:1 and 1 : 1 by weight.
27. The pharmaceutical composition according to claim 26, wherein the ratio of carboxymethyl cellulose calcium to carboxymethyl cellulose sodium is in the range of 4:1 and 2:1 by weight.
28. The pharmaceutical composition according to claim 1, wherein said composition can comprise cefpodoxime in the range of 20-800 mg or its pharmaceutically acceptable esters, salts, hydrates, solvates or a combination thereof in an equal amount.
29. The pharmaceutical composition according to claim 1, wherein said composition can comprise 5-60% of cefpodoxime or its pharmaceutically acceptable esters, solvates, hydrates, enantiomers, racemates, organic salts, inorganic salts, polymorphs, crystalline and amorphous forms in proportion to total amount of unit dose.
30. The pharmaceutical composition according to claim 1, wherein said composition can comprise 5-60 % of cefpodoxime; binder in the range of 0-40%; glidant in the range of 0.5-5%; lubricant in the range of 1-10%; humectant in the range of 0-40%; disintegrant and/or disintegrants in the range of 0-20%; diluent in the range of 35-65%; basic agent in the range of 0-40%; acidic agent in the range of 0.1-40%; taste regulating agent in the range of 1-25%; viscosity agent and/or agents in the range of 2-15%; flavouring agents in the range of 0.1-5%; preservative agent in the range of 0-5% and optionally effervescent couple in the range of 0-85% in proportion to the total weight of unit dose amount.
31. The pharmaceutical composition claimed in any preceding claims, wherein said composition comprises clavulanic acid or derivatives thereof in addition to cefpodoxime as the active agent.
32. The pharmaceutical composition according to claim 31, wherein clavulanic acid can be in the form of its solvates, hydrates, enantiomers, racemates, organic salts, inorganic salts, polymorphs, crystalline and amorphous forms or in free form and/or a combination thereof.
33. The pharmaceutical composition according to claim 32, wherein potassium clavulanate is used in said composition.
34. Use of viscosity agent combination comprising hydroxypropyl cellulose and at least one carboxymethyl cellulose derivative agent combination for production of a drug formulation comprising cefpodoxime proxetil.
35. A method for preparation of the pharmaceutical composition as claimed in any of the claims above, wherein said method comprises granulation of the active agent cefpodoxime proxetil by conventional wet and/or dry granulation methods; or powdering cefpodoxime proxetil and other excipients after mixing them by dry blending method and optionally compressing tablets.
6. The pharmaceutical composition according to claim 1, wherein said composition is used for production of a drug prepared so as to be used in the treatment of diseases related with infections caused by gram negative and gram positive bacteria.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TR2010/09168A TR201009168A2 (en) | 2010-11-05 | 2010-11-05 | Water dispersible cefpodoxime proxetil formulations. |
| TR2010/09168 | 2010-11-05 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2012060790A2 true WO2012060790A2 (en) | 2012-05-10 |
| WO2012060790A3 WO2012060790A3 (en) | 2012-09-20 |
Family
ID=45446166
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/TR2011/000255 Ceased WO2012060790A2 (en) | 2010-11-05 | 2011-11-03 | Water dispersible cefpodoxime proxetil formulations |
| PCT/TR2011/000251 Ceased WO2012060786A2 (en) | 2010-11-05 | 2011-11-03 | Cefpodoxime proxetil formulations comprising viscosity agent |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/TR2011/000251 Ceased WO2012060786A2 (en) | 2010-11-05 | 2011-11-03 | Cefpodoxime proxetil formulations comprising viscosity agent |
Country Status (2)
| Country | Link |
|---|---|
| TR (1) | TR201009168A2 (en) |
| WO (2) | WO2012060790A2 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013151517A1 (en) * | 2012-04-04 | 2013-10-10 | Mahmut Bilgic | Tablet formulations comprising cefpodoxime proxetil and clavulanic acid |
| CN103142506B (en) * | 2013-04-03 | 2015-02-25 | 天津医药集团津康制药有限公司 | Cefpodoxime proxetil granules and preparation method thereof |
| CN103230367B (en) * | 2013-05-07 | 2014-11-12 | 山东罗欣药业集团股份有限公司 | Cefpodoxime proxetil composition dry suspension and preparation method thereof |
| MX2017007287A (en) * | 2014-12-01 | 2017-08-25 | Sun Pharmaceutical Ind Ltd | Extended-release cefpodoxime proxetil composition. |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0049118A2 (en) | 1980-09-30 | 1982-04-07 | Sankyo Company Limited | Cephalosporin derivatives, their preparation and compositions containing them |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA006974B1 (en) * | 2001-02-27 | 2006-06-30 | Ранбакси Лабораторис Лимитед | Oral pharmaceutical composition of cefpodoxime proxetil |
| TW200404550A (en) * | 2002-07-08 | 2004-04-01 | Sankyo Co | Cepharospolin formulation for oral use |
| JP4526247B2 (en) * | 2002-07-08 | 2010-08-18 | 第一三共株式会社 | Oral cephalosporins |
| KR20050062514A (en) * | 2002-07-16 | 2005-06-23 | 랜박시 래보러터리스 리미티드 | Dispersible tablets for oral administration |
| EP1883393A2 (en) * | 2005-05-05 | 2008-02-06 | Lupin Ltd. | Stabilized oral pharmaceutical compositions of cephalosporins |
| TR201002878A2 (en) * | 2010-04-13 | 2011-10-21 | Bi̇lgi̇ç Mahmut | Pharmaceutical compositions comprising cefpodoxime proxetil. |
-
2010
- 2010-11-05 TR TR2010/09168A patent/TR201009168A2/en unknown
-
2011
- 2011-11-03 WO PCT/TR2011/000255 patent/WO2012060790A2/en not_active Ceased
- 2011-11-03 WO PCT/TR2011/000251 patent/WO2012060786A2/en not_active Ceased
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0049118A2 (en) | 1980-09-30 | 1982-04-07 | Sankyo Company Limited | Cephalosporin derivatives, their preparation and compositions containing them |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012060790A3 (en) | 2012-09-20 |
| TR201009168A2 (en) | 2012-05-21 |
| WO2012060786A2 (en) | 2012-05-10 |
| WO2012060786A3 (en) | 2012-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2528589B1 (en) | Stable efervescent formulations comprising cefaclor | |
| EP2568959A2 (en) | Formulations comprising a third generation cephalosporin and clavulanic acid | |
| WO2012060788A1 (en) | Formulations of cephalosporins with controlled moisture content | |
| WO2012060790A2 (en) | Water dispersible cefpodoxime proxetil formulations | |
| WO2012026907A2 (en) | Cefpodoxime proxetil formulations | |
| EP2515860B1 (en) | Improved pharmaceutical compositions comprising cefdinir | |
| WO2011142730A1 (en) | Pharmaceutical composition comprising cefixime and clavulanic acid derivative compound | |
| WO2011129792A1 (en) | Water dispersible formulations comprising cefpodoxime proxetil | |
| US20130129791A1 (en) | Preparations of effervescent formulations comprising second and third generation cephalosporin and uses thereof | |
| WO2011093828A2 (en) | Solid dosage forms comprising cefprozil | |
| EP2566451B1 (en) | Pharmaceutical compositions comprising cefditoren pivoxil | |
| EP2515858A1 (en) | Pharmaceutical composition with high purity | |
| WO2012060787A1 (en) | Oral dosage forms comprising cefdinir and carboxymethyl cellulose calcium | |
| WO2012060791A2 (en) | Production method for pharmaceutical compositions comprising cefdinir | |
| EP2515859A1 (en) | Rapidly dispersing effervescent formulation | |
| WO2012026908A2 (en) | Cefpodoxime proxetil formulations comprising taste regulating agent | |
| EP2575812A2 (en) | Pharmaceutical composition comprising cefpodoxime proxetil and clavulanic acid | |
| WO2011139255A2 (en) | Pharmaceutical compositions comprising cefetamet | |
| WO2012060792A1 (en) | Pharmaceutical compositions comprising minimum 6 % of disintegrants by weight | |
| WO2011152808A1 (en) | Formulation comprising cefpodoxime proxetil and clavulanic acid | |
| WO2012060793A2 (en) | Process for the preparation of cefdinir formulations | |
| WO2012078121A2 (en) | Solid oral dosage form comprising cefdinir | |
| WO2013151517A1 (en) | Tablet formulations comprising cefpodoxime proxetil and clavulanic acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11805269 Country of ref document: EP Kind code of ref document: A2 |
|
| NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 11805269 Country of ref document: EP Kind code of ref document: A2 |